Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia

Mutant isocitrate dehydrogenase 1 (mIDH1) inhibitors have shown single-agent activity in relapsed/refractory acute myeloid leukemia (AML), even though most patients eventually relapse. We evaluated the efficacy and molecular mechanism of the combination treatment with azacitidine, which is currently...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Haematologica
Main Authors: Chaturvedi, Anuhar, Gupta, Charu, Gabdoulline, Razif, Borchert, Nora M., Goparaju, Ramya, Kaulfuss, Stefan, Gorlich, Kerstin, Schottmann, Renate, Othman, Basem, Welzenbach, Julia, Panknin, Olaf, Wagner, Markus, Geffers, Robert, Ganser, Arnold, Thol, Felicitas, Jeffers, Michael, Haegebarth, Andrea, Heuser, Michael
Formato: Artigo
Idioma:Inglês
Publicado: Fondazione Ferrata Storti 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7849562/
https://ncbi.nlm.nih.gov/pubmed/32241846
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.236992
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares